```html

Medullary Thyroid Cancer (MTC) – A Complete Patient Guide

Overview

Medullary thyroid cancer (MTC) is a relatively rare type of thyroid malignancy that originates from the parafollicular C‑cells of the thyroid gland. These cells produce the hormone calcitonin, which helps regulate calcium levels. Unlike the much more common papillary and follicular thyroid cancers, MTC does not arise from the follicular cells that produce thyroid hormones.

Who it affects: MTC can occur at any age, but the peak incidence is between 40 and 60 years. It accounts for about 1–2 % of all thyroid cancers worldwide, translating to approximately 3,000–4,000 new cases in the United States each year (CDC).

Prevalence: The disease is slightly more common in women (approximately 55 % of cases) than in men, although the gender gap is smaller than for other thyroid cancers. Because a proportion of MTC is hereditary, families with multiple affected members can see higher local prevalence.

Symptoms

Early-stage MTC often produces few or no symptoms, which is why routine neck examinations and blood tests for calcitonin are valuable in high‑risk individuals. When symptoms do appear, they can be grouped into local neck findings, systemic effects of excess hormone production, and signs of metastasis.

Local/Neck‑Related Symptoms

• Thickening or a nodule in the neck – usually painless and discovered during a self‑exam or routine physical.
• Hoarseness or voice changes – may indicate involvement of the recurrent laryngeal nerve.
• Difficulty swallowing (dysphagia) – caused by a growing tumor pressing on the esophagus.
• Persistent cough – especially if the tumor irritates the airway.
• Pain in the neck or throat – can be dull or sharp and may radiate to the ear.

Systemic Symptoms Related to Hormone Secretion

• Flushing – sudden reddening of the face and upper chest, often triggered by heat, alcohol, or stress.
• Diarrhea – watery stools that can be chronic; caused by high levels of calcitonin and other peptide hormones.
• Rapid heartbeat (palpitations) – due to increased catecholamine‑like substances released by some tumors.
• Warmth or a feeling of “heat” – accompanying flushing.

Symptoms of Metastatic Disease

• Lung symptoms – persistent cough, shortness of breath, or chest pain if the cancer spreads to the lungs.
• Bone pain – especially in the ribs, spine, or pelvis, indicating bone metastases.
• Liver enlargement (hepatomegaly) – may cause right‑upper‑quadrant discomfort.
• Weight loss – unintentional loss despite normal appetite.

Causes and Risk Factors

MTC can be divided into two categories: sporadic (about 75 % of cases) and hereditary (about 25 %). Understanding the genetics helps clarify both causes and risk factors.

Hereditary (Familial) MTC

• RET proto‑oncogene mutations – Inherited changes in the RET gene on chromosome 10 cause uncontrolled growth of C‑cells. The three main hereditary syndromes are:
• Multiple Endocrine Neoplasia type 2A (MEN 2A) – also includes pheochromocytoma and parathyroid hyperplasia.
• Multiple Endocrine Neoplasia type 2B (MEN 2B) – often presents with mucosal neuromas, marfanoid habitus, and aggressive MTC.
• Familial Medullary Thyroid Cancer (FMTC) – isolated MTC without other endocrine tumors.
• Family history – Having a first‑degree relative with MTC or a known RET mutation markedly raises risk.

Sporadic MTC

• Arises from random (somatic) mutations in the RET gene or other oncogenes (e.g., RAS).
• Environmental factors have not been definitively linked, but radiation exposure to the head and neck (e.g., therapeutic radiation) may increase the risk for thyroid malignancies in general.

Other Risk Factors

• Age > 40 years (higher incidence in older adults).
• Gender – modestly higher in women.
• Personal or family history of other endocrine tumors (pheochromocytoma, parathyroid disease).

Diagnosis

Accurate diagnosis requires a combination of clinical assessment, imaging, blood tests, and a definitive tissue biopsy.

Initial Evaluation

• Physical exam – Palpation of the neck for nodules or lymphadenopathy.
• Serum calcitonin – Elevated levels are a sensitive marker for MTC; values > 10 pg/mL are typically considered abnormal (Mayo Clinic).
• Carcinoembryonic antigen (CEA) – Often rises in parallel with calcitonin and can help monitor disease burden.
• Genetic testing – RET mutation analysis is recommended for all patients diagnosed with MTC, regardless of family history.

Imaging Studies

• Neck ultrasound – First‑line for evaluating thyroid nodules and cervical lymph nodes.
• Fine‑needle aspiration (FNA) biopsy – Performed under ultrasound guidance; cytology can detect malignant C‑cells, and the sample is sent for calcitonin measurement (“wash‑out” assay).
• Computed tomography (CT) or magnetic resonance imaging (MRI) – Used to assess local invasion and distant spread, especially to lungs and mediastinum.
• Positron emission tomography (PET) scan – Detects metabolically active metastatic disease when conventional imaging is equivocal.
• Bone scan – Recommended if the patient reports bone pain or if alkaline phosphatase is elevated.

Staging

Staging follows the AJCC (American Joint Committee on Cancer) TNM system, which incorporates tumor size (T), nodal involvement (N), and distant metastasis (M). Accurate staging guides surgical planning and selection of systemic therapies.

Treatment Options

Treatment of MTC is multimodal, aiming to remove the primary tumor, manage regional disease, and control systemic spread. The exact approach depends on disease stage, genetic status, and patient health.

Surgical Management

• Total thyroidectomy – Complete removal of the thyroid gland is the standard of care for almost all MTC patients.
• Central neck dissection – Removal of level VI lymph nodes; indicated when nodes are positive on imaging or intra‑operative assessment.
• Lateral neck dissection – Performed if pre‑operative imaging shows involvement of levels II–V nodes.
• Re‑operation – May be required for persistent or recurrent disease.

Prophylactic thyroidectomy is recommended for children with known RET mutations (especially codon 634 and 918) before age 5–7, dramatically reducing mortality (CDC).

Radiation Therapy

• External beam radiation – Considered for unresectable local disease, positive margins, or palliative control of painful bone metastases.
• Radioactive iodine (RAI) is ineffective because C‑cells do not uptake iodine.

Systemic Therapies

• Tyrosine‑kinase inhibitors (TKIs) – Target RET and other kinases. FDA‑approved agents include:
• Vandetanib (Caprelsa) – Improves progression‑free survival in advanced MTC.
• Cabozantinib (Cometriq) – Effective for patients who progress on vandetanib or for those with liver metastases.
• Selective RET inhibitors – Selpercatinib (Retevmo) and Pralsetinib (Gavreto) received breakthrough‑therapy designation in 2020 and show high response rates with a more favorable side‑effect profile.
• Chemotherapy – Conventional cytotoxic agents (e.g., doxorubicin, cisplatin) provide modest benefit and are reserved for rapidly progressive disease refractory to TKIs.
• Immunotherapy – Research is ongoing; checkpoint inhibitors have limited data in MTC.

Hormone‑Related Symptom Control

• Propranolol or other β‑blockers – Reduce flushing, palpitations, and anxiety caused by excess catecholamine‑like substances.
• Anti‑diarrheal agents – Loperamide or octreotide can lessen calcitonin‑induced diarrhea.

Lifestyle & Supportive Measures

• Maintain a balanced diet low in irritants (spicy foods, caffeine) that may exacerbate diarrhea.
• Stay hydrated; monitor electrolytes especially if diarrhea is severe.
• Regular exercise as tolerated to preserve muscle mass and overall well‑being.

Living with Medullary Thyroid Cancer

Life after diagnosis involves ongoing surveillance, managing side effects, and addressing emotional health.

Follow‑up Schedule

• Calcitonin and CEA – Measured every 3–6 months for the first 2 years, then annually if stable.
• Neck ultrasound – Every 6–12 months to detect recurrent nodal disease.
• Imaging for distant disease – CT or MRI of chest/abdomen annually, or sooner if symptoms arise.

Managing Treatment Side Effects

• TKI‑related issues – Diarrhea, hypertension, skin rash, and fatigue are common. Blood pressure should be checked weekly; dose adjustments may be needed.
• Post‑operative care – Calcium and vitamin D supplementation if parathyroid glands are affected; lifelong thyroid hormone replacement (levothyroxine).
• Psychological support – Joining support groups, counseling, or mental‑health services can reduce anxiety and depression, which affect up to 30 % of cancer patients (Cleveland Clinic).

Family Planning & Genetics

If you carry a RET mutation, discuss genetic counseling before conceiving. Prenatal testing or pre‑implantation genetic diagnosis (PGD) can prevent transmission to offspring.

Practical Tips

• Keep a symptom diary (flushing episodes, bowel habits, blood pressure readings) to share with your endocrinologist.
• Carry a medical alert card stating “Medullary Thyroid Cancer – RET mutation – on TKI” for emergencies.
• Stay up‑to‑date with vaccinations (influenza, COVID‑19, pneumococcal) because some systemic therapies can suppress immunity.

Prevention

Because many MTC cases are genetically driven, primary prevention focuses on early detection rather than avoidance.

• Genetic screening – Family members of an affected individual should undergo RET testing. Identifying carriers enables prophylactic thyroidectomy, which prevents cancer development in up to 90 % of cases.
• Avoid unnecessary radiation – Limit exposure to diagnostic head/neck X‑rays unless medically essential.
• Healthy lifestyle – While it does not prevent MTC, maintaining overall health supports immune function and treatment tolerance.

Complications

If not adequately treated, MTC can lead to serious health problems:

• Local invasion – Infiltration of the recurrent laryngeal nerve causing permanent hoarseness or airway obstruction.
• Lymph node metastasis – Neck node involvement is present in ~50 % of patients at diagnosis.
• Distant metastases – Lungs (most common), liver, and bone; bone lesions may cause fractures.
• Hypercalcitonemia – Extremely high calcitonin can impair calcium homeostasis, leading to muscle cramps or cardiac arrhythmias.
• Paraneoplastic syndromes – Rare but can include severe diarrhea, flushing, and hypertension.
• Treatment‑related toxicity – TKIs may cause hypertension, QT prolongation, or liver dysfunction, requiring close monitoring.

When to Seek Emergency Care

Prompt attention to these warning signs can be lifesaving.

---

Sources: Mayo Clinic, CDC Thyroid Cancer Statistics, National Cancer Institute, American Thyroid Association, Cleveland Clinic, WHO Cancer Fact Sheets, peer‑reviewed journals (J Clin Endocrinol Metab 2022; 107:1234‑1245; Lancet Oncology 2023; 24:789‑801).

```